| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 16198.7 | 15299.9 | 14478.3 |
| Other income | 517.3 | 723.6 | 469.9 |
| Total income | 16716.0 | 16023.5 | 14948.2 |
| Profit before exceptional items & tax | 4428.2 | 4302.9 | 4167.6 |
| Exceptional items | -1268.8 | -204.1 | 0.0 |
| Profit before tax | 3159.4 | 4098.8 | 4167.6 |
| Net profit | 1995.1 | 2901.2 | 3124.9 |
| Operating margin | 18.9% | 25.6% | 27.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -36.20% |
|---|---|
| Net profit, quarter on quarter | -31.20% |
| Revenue, year on year | +11.90% |
| Operating profit, year on year | +5.80% |
| Operating profit, quarter on quarter | +9.30% |
BSE results filing, NSE: SUNPHARMA. Figures extracted from the filing.
Sun Pharmaceutical Industries Ltd: key numbers
- Share price
- ₹1,805.30
- Market cap
- ₹4,33,152 Cr
- Revenue (annual)
- ₹58,462 Cr
- Net profit (annual)
- ₹11,479 Cr
- P/E (TTM)
- 35.8×Sector 48.7×
- Promoter holding
- 52.68%-1.80% QoQ
- FII holding
- 14.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sun Pharmaceutical Industries Ltd
All →Sun Pharmaceutical Industries Other Announcement
Sun Pharma's board appointed Deloitte as Statutory Auditors under mandatory rotation, effective from the FY 2026-27 AGM. This follows SRBC & CO's second five-year term completion.
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
Sun Pharmaceutical Industries Debt & Borrowing: ₹7,816 Cr
Sun Pharma completed allotment of ₹7,816 crore NCDs via private placement, exercising its greenshoe option of ₹816 crore. The unsecured debentures carry 8.05–8.20% coupons maturing October 2031.
- Value
- ₹7,816 Cr
- Execution
- 5 years and 1 day (26 Oct 2026 to 27 Oct 2031)
Sun Pharmaceutical Industries Business Update
Sun Pharma's drug UNLOXCYT received Category 2A preferred designation in updated NCCN guidelines for treating locally advanced cutaneous squamous cell carcinoma.
Sun Pharmaceutical Industries Other Announcement
Sun Pharmaceutical Industries submitted the quarterly confirmation certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, as received from their RTA.
Sun Pharmaceutical Industries Credit Rating
Sun Pharma received credit ratings from CRISIL and ICRA for its proposed NCD programme and reaffirmed existing facility ratings.